Rosiglitazone may increase the risk of chronic heart failure (HF) in patients receiving insulin for type 2 diabetes mellitus

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1030, 2004-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thiazolidinediones may double the risk of heart failure (HF) among patients receiving such drugs for type 2 diabetes mellitus

By  

Reactions Weekly, Vol. 1, Iss. 1162, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Treatment with rosiglitazone reduces ambulatory BP and increases insulin sensitivity in patients with hypertension and type 2 diabetes mellitus

By  

Inpharma, Vol. 1, Iss. 1458, 2004-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Metformin may reduce the risk of cancer in patients with type 2 diabetes mellitus

By  

Inpharma, Vol. 1, Iss. 1491, 2005-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Retrospective Analysis of Rosiglitazone and Macular Oedema in Patients with Type 2 Diabetes Mellitus

By Tatti Patrizio  

Clinical Drug Investigation, Vol. 28, Iss. 5, 2008-01 ,pp. : 327-332

Adis International

Access to resources Recommend Favorite

A fixed combination of rosiglitazone plus metformin improves glycaemic control and cardiovascular risk factors in patients with type 2 diabetes mellitus (T2DM)

By  

Inpharma, Vol. 1, Iss. 1546, 2006-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite